Cannabis tolerance and CB1 receptors: neuroscience Beetle Print

Cannabis Tolerance and CB1 Receptors: What Really Happens in Your Brain

SCIENCEEDU ยท Updated August 2026

Cannabis Tolerance and CB1 Receptors: What Really Happens in Your Brain

๐Ÿง  "I need more and more just to feel the same thing" is the most common phrase among regular cannabis users, and it's not a subjective impression โ€” it's neurobiology you can actually measure with brain imaging technology. CB1 receptors, the main gateway through which THC reaches the nervous system, physically change in number and behavior with repeated use. This guide explains, drawing on real PET neuroimaging studies and pharmacology, exactly what cannabis tolerance is, how it builds up, why not all effects tolerate at the same pace, and what the science says about recovery time.

Table of Contents

  1. The endocannabinoid system in 60 seconds
  2. What a CB1 receptor is (and why it's the key piece)
  3. How THC builds tolerance: the mechanism step by step
  4. The evidence: what neuroimaging studies show
  5. Timeline: how long tolerance takes to develop
  6. Not all tolerance is equal: fast effects vs. slow effects
  7. Why memory doesn't follow the same pattern
  8. Recovery timeline: getting back to baseline
  9. Genetics: why not everyone develops tolerance the same way
  10. Adolescence and CB1: a more vulnerable brain
  11. Cross-tolerance: synthetic cannabinoids and CB1
  12. The opposite effect: sensitization in occasional users
  13. CBD and tolerance: does it modulate the system?
  14. Route of consumption: do smoking, vaping, or edibles build tolerance differently?
  15. Implications for patients: titration and clinical reassessment
  16. Table: how fast tolerance builds by effect
  17. Myths vs. reality
  18. Frequently asked questions
20-30%
Reduction in cortical CB1 receptors after 2 weeks of daily use
48h
Point at which recovery of CB1 sensitivity starts to be measurable
~4
Weeks of abstinence for CB1 density to return close to baseline
15+
Known genetic variants of the CB1 receptor (CNR1) in humans

1. The endocannabinoid system in 60 seconds ๐Ÿงฌ

Before talking about tolerance, it helps to understand exactly which system is being altered. The endocannabinoid system is a signaling network present throughout the body, made up of three components: the receptors (mainly CB1 and CB2), the molecules that naturally activate them (endocannabinoids, chiefly anandamide and 2-arachidonoylglycerol, or 2-AG), and the enzymes that produce and break down those molecules. Its core biological function is to maintain balance, or homeostasis, across processes as varied as mood, appetite, pain perception, memory, sleep, and immune response.

Anandamide and 2-AG are not the same thing

Both are endocannabinoids produced by the body itself, but they behave differently on the same receptors: anandamide acts as a partial agonist of CB1 and CB2, while 2-AG is a full agonist, more potent at both receptors. This difference matters because the THC in the cannabis plant mimics the action of these natural messengers โ€” but much more intensely and for much longer โ€” and that's where the problem of tolerance begins.

A system designed to run on brief, self-limiting bursts of signaling ends up, with repeated THC use, exposed to artificially prolonged and intense activation. True to its homeostatic logic, the body responds by trying to bring the system back to a point of balance โ€” and that adaptive response is, essentially, tolerance.

2. What a CB1 receptor is (and why it's the key piece) ๐Ÿ”‘

The most abundant receptor in the central nervous system

The CB1 receptor is one of the most highly expressed G protein-coupled receptors in the entire human brain, and it's considered the main driver of THC's effects on the central nervous system. It's especially concentrated in the hippocampus (memory), the prefrontal cortex (decision-making), the basal ganglia and cerebellum (motor coordination), and the amygdala (emotional processing) โ€” which explains why cannabis affects memory, judgment, coordination, and mood all at once.

The CB2 receptor, by contrast, is concentrated mostly in peripheral tissues, especially those of the immune system, and plays a far more limited role in direct psychoactive effects. When people colloquially talk about "getting high," CB1 is almost always the main character: THC binds to it with considerable affinity and, unlike the natural endocannabinoids that break down within minutes, stays active in the body for hours.

3. How THC builds tolerance: the mechanism step by step โš™๏ธ

Tolerance isn't a single phenomenon โ€” it's a sequence of at least three distinct neurobiological adaptations that occur progressively with repeated THC exposure.

Step 1 โ€” Desensitization

With sustained exposure to an agonist like THC, the CB1 receptor starts losing efficiency in how it couples with the G proteins that carry the signal inside the cell. It's the equivalent of a doorbell that's still there, but rings a little quieter each time it's pressed.

Step 2 โ€” Internalization

If exposure continues, the cell starts physically removing CB1 receptors from the membrane surface, pulling them inward through a process called endocytosis. Those internalized receptors are no longer available to be activated by THC or by the body's own natural endocannabinoids, although at this stage the process is still relatively reversible.

Step 3 โ€” Downregulation (net receptor reduction)

With prolonged daily use, some of those internalized receptors don't get recycled back to the surface โ€” they're degraded by the cell instead. The result is a net, measurable reduction in the total number of available CB1 receptors โ€” not just "switched off" temporarily, but effectively fewer in number. This is the phenomenon that neuroimaging studies are able to visualize directly.

These three steps explain why tolerance doesn't show up all at once: first the system becomes less sensitive while the receptor is still in place, then it starts "hiding" receptors, and finally it reduces their actual number. It's an adaptive process โ€” the brain trying to protect itself from sustained overstimulation โ€” not random damage.

4. The evidence: what neuroimaging studies show ๐Ÿ”ฌ

The landmark study: Hirvonen et al., 2012

One of the most cited studies in this field, published in Molecular Psychiatry, used positron emission tomography (PET) to compare CB1 receptor availability in chronic daily cannabis users versus healthy controls. The central finding: users showed roughly 20% fewer CB1 receptors in cortical brain regions, correlated with years of use โ€” but not in subcortical regions, pointing to a selective, region-specific downregulation rather than something spread across the whole organ.

The key finding: it was reversible

The same study followed 14 of the chronic users through four weeks of monitored abstinence and repeated the PET scan. The result showed a measurable recovery in CB1 receptor availability in the same regions where the reduction had previously been detected โ€” the first direct demonstration in humans that this neuroadaptation is not permanent.

Later studies, such as the work by Ceccarini and colleagues published in Addiction Biology using the tracer [18F]MK-9470, confirmed the overall pattern: heavy chronic use is associated with lower CB1 availability in specific cortical regions, varying with the intensity and duration of use. In especially heavy users โ€” defined as those smoking several times a day โ€” the reduction in CB1 availability lands in the 20% to 30% range across multiple brain regions.

5. Timeline: how long tolerance takes to develop โฑ๏ธ

Faster than most people assume

Neuroimaging studies show measurable CB1 receptor downregulation after as little as two weeks of daily use. This runs counter to the popular idea that "real" tolerance takes months to build โ€” at the receptor level, the change is detectable almost immediately in daily users, even though the subjective magnitude (how much the person actually notices it) keeps increasing over time.

The speed of downregulation, moreover, is not uniform across brain regions. CB1 receptors in the hippocampus โ€” the region most involved in memory โ€” show the greatest degree of desensitization and downregulation in response to repeated THC exposure, while adaptations in the striatum (involved in movement and reward) develop more slowly, but also recover faster once use stops.

6. Not all tolerance is equal: fast effects vs. slow effects โš–๏ธ

The "high" tolerates before other effects do

Pharmacological evidence shows a consistent pattern: the subjective psychoactive effect โ€” the "high" โ€” tends to blunt more noticeably and more quickly than other effects of cannabis, such as anxiety reduction or appetite stimulation, which tend to stick around relatively longer even after the user already feels it "doesn't hit the same."

This has an important practical implication for two very different types of users. For the recreational user, it means that chasing the original intensity of the high by increasing the dose may not pay off proportionally: the system has adapted unevenly, and increasing the amount doesn't necessarily reverse tolerance at the same rate across all effects. For the medical cannabis user, it means the therapeutic effect that motivated treatment โ€” pain control, appetite, or nausea relief, for example โ€” may persist longer than the euphoric sensation, which is clinically relevant when assessing whether a treatment is still working even though "it doesn't get you as high anymore."

7. Why memory doesn't follow the same pattern ๐Ÿงฉ

The most counterintuitive finding

Unlike euphoria, the working memory impairment associated with cannabis use doesn't appear to ease at the same rate with repeated use. Available evidence indicates that regular users can continue to show measurable working memory deficits even after months of regular use, despite having already developed noticeable tolerance to the subjective feeling of intoxication.

The most plausible explanation ties directly back to the anatomy described in section 5: the hippocampus, the brain region most associated with memory consolidation, is precisely the region that shows the most pronounced CB1 downregulation in response to repeated THC. In other words, the same neuroadaptation that reduces the intensity of the "high" in other regions may be operating differently โ€” or with different functional consequences โ€” in the memory circuit, which helps explain why "feeling less high" doesn't automatically mean "no cognitive effect."

8. Recovery timeline: getting back to baseline ๐Ÿ“ˆ

Abstinence time What the evidence shows
0-48 hours Window in which the onset of CB1 sensitivity recovery starts to be recorded; subjective effects still very limited.
~2 weeks Substantial improvement across several regions; the striatum and hippocampus show some of the fastest recovery rates.
~4 weeks Neuroimaging studies (Hirvonen et al.) show measurable recovery of CB1 availability in previously affected cortical regions, approaching baseline levels in daily users.
6-8 weeks Range that some very heavy, long-term users reference as an extended benchmark for fuller recovery, though there is less controlled literature specific to this threshold.
Speed depends on the brain region, not a single number

It's a mistake to treat "tolerance recovery" as if it were a single switch that resets all at once at four weeks. Neuroimaging evidence shows that different brain regions recover CB1 availability at different rates โ€” the hippocampus relatively fast, the cortex more gradually โ€” which likely explains why many users describe recovery of sensations happening "in layers": first they notice appetite or sleep coming back into clearer focus, and only later, the full subjective intensity of the effect.

For a practical, step-by-step guide on structuring a tolerance break (t-break) โ€” recommended duration based on your usage pattern, what to expect at each stage, and how to minimize the discomfort of resetting โ€” Beetle Print has a dedicated guide on exactly that topic within this same educational section.

9. Genetics: why not everyone develops tolerance the same way ๐Ÿงฌ

The FAAH gene and anandamide

The enzyme FAAH (fatty acid amide hydrolase) is responsible for breaking down anandamide, one of the two main endocannabinoids described in section 1. There's a genetic variant of FAAH, present in roughly a third of the population, that significantly alters how the brain's reward circuit processes THC exposure โ€” with documented implications, in preclinical models, for individual vulnerability to the reinforcing effects of cannabis.

The CB1 receptor itself has variants

The CNR1 gene, which codes for the CB1 receptor, has at least 15 known variants in humans, and in some cases these variations can noticeably alter the receptor's sensitivity to molecules like THC. Gene-environment interaction studies have found associations between certain CNR1 genotypes and differences in white matter volume and neurocognitive impairment in cannabis users, suggesting the same exposure can have different consequences depending on individual genetic makeup.

This helps explain, at least partly, something any regular user recognizes anecdotally: two people with an apparently identical consumption pattern โ€” same amount, same frequency, same product โ€” can develop noticeably different degrees of tolerance. Individual genetics of the endocannabinoid system is, alongside frequency and dose, one of the factors driving that variability.

10. Adolescence and CB1: a more vulnerable brain ๐ŸŽ“

A system still under construction

Adolescence is the period of highest risk for starting cannabis use, and it coincides with a phase in which the endocannabinoid system and brain reward circuits are still under active development. Preclinical research on the FAAH genetic variant mentioned in the previous section has found that it can alter mesolimbic dopaminergic circuit activity and change CB1 receptor levels in the ventral tegmental area during adolescence โ€” with documented differences by sex in animal models.

This finding reinforces, from a neuroscience standpoint and not just general caution, why early THC exposure is treated differently in the scientific literature compared with use in an already-developed adult brain: it's not just a matter of "less experience," but of a receptor system still in active maturation, potentially more susceptible to lasting remodeling under repeated exposure.

11. Cross-tolerance: synthetic cannabinoids and CB1 โš ๏ธ

Why this connects to the risk of Spice/K2

The same CB1 receptor that mediates THC's effects is also the target of synthetic cannabinoids like those found in Spice or K2 (see this series' dedicated article on that topic). The key difference is that many of these synthetic compounds act as high-affinity full agonists at CB1 โ€” unlike THC, which is only a partial agonist โ€” producing much more intense receptor activation and, as a result, a considerably greater potential for downregulation and adverse effects at equivalent doses.

For a user who has already developed THC tolerance through habitual use, this has a direct safety implication: tolerance built up against natural cannabis does not reliably protect against the effects โ€” or the toxicity โ€” of an unknown synthetic cannabinoid, precisely because the receptor activation mechanism is qualitatively different, not just quantitatively stronger.

12. The opposite effect: sensitization in occasional users ๐Ÿ”„

When the opposite of tolerance happens

Not every consumption pattern produces downregulation. In very occasional users or those new to THC โ€” a particularly relevant case with edibles, where absorption variability is already higher than smoking โ€” the reverse phenomenon can occur: an initial sensitivity that's more pronounced than expected at relatively low doses, simply because the receptor system hasn't been previously exposed and hasn't developed any degree of protective adaptation.

This is especially useful for explaining why two people with "the same perceived tolerance" โ€” for example, both describing themselves as "moderate" users โ€” can react very differently to the same product: recent exposure history, not just stated general frequency, largely determines where the CB1 receptor system sits at any given moment.

13. CBD and tolerance: does it modulate the system? ๐ŸŒฟ

A different mechanism, not a tolerance "antidote"

CBD doesn't act as a direct CB1 agonist the way THC does, and its relationship with the endocannabinoid system is considerably more indirect and complex โ€” among other pathways, it has been proposed that it can modulate anandamide availability by interfering with its reuptake or enzymatic breakdown. This has fueled the popular idea that "combining CBD reduces THC tolerance," but robust, specific clinical evidence for that exact effect in humans is still limited and shouldn't be treated as an established fact.

What is better documented is the so-called entourage effect โ€” how the presence of CBD can modulate the subjective THC experience, softening some anxiogenic effects in certain users โ€” but that's a different phenomenon from "reversing" the CB1 receptor downregulation described in the previous sections. Treating CBD as a guaranteed tolerance-management tool goes, for now, beyond what solid scientific evidence supports.

14. Route of consumption: do smoking, vaping, or edibles build tolerance differently? ๐Ÿ’จ

The underlying mechanism is the same, the kinetics change

Regardless of whether THC reaches the CB1 receptor by smoking, vaping, or orally through an edible, the underlying neuroadaptive process โ€” desensitization, internalization, and downregulation described in section 3 โ€” is the same: what activates the receptor is the THC molecule itself (or its active metabolite 11-hydroxy-THC in the case of edibles), not the method of administration. What does change meaningfully is the kinetics: the speed and duration with which THC reaches and saturates the receptor.

Why this matters for perceived tolerance

Smoking or vaping produces fast, relatively short peaks of THC blood concentration, while edibles create a slower-onset but considerably more prolonged exposure, due to first-pass liver metabolism and the formation of 11-hydroxy-THC, a metabolite with its own strong capacity to activate CB1. A daily edibles-based consumption pattern can, in practice, keep the CB1 receptor under sustained activation for more hours a day than an equivalent smoked pattern, which could theoretically influence the speed of downregulation โ€” although direct comparative research between routes of use and tolerance rate in humans is still limited.

This also partly explains the phenomenon described in section 12: a habitual smoker who tries edibles without prior experience with that route can experience a disproportionately intense response, not because their overall THC tolerance doesn't exist, but because the exposure pattern their CB1 receptor system is adapted to โ€” short, intense peaks โ€” is different from the one edibles generate: a more gradual, sustained exposure.

15. Implications for patients: titration and clinical reassessment ๐Ÿฉบ

Why tolerance matters in medical cannabis

For patients under medical cannabis treatment, CB1 downregulation has a direct practical consequence: the initially effective dose can stop being effective over time, not because the underlying condition has worsened, but because the receptor system has adapted to continued exposure. This is exactly the same neurobiological mechanism described in section 3, applied to a therapeutic rather than recreational context.

Titration isn't just "raising the dose"

Since, as explained in section 6, different cannabis effects don't tolerate at the same rate, a patient whose main therapeutic effect โ€” pain relief, for example โ€” tolerates more slowly than the subjective feeling of intoxication may not necessarily need to increase the dose just because they "don't feel it as much" in terms of psychoactive effect. This is precisely why dose adjustments in medical cannabis treatment should be reviewed with the responsible medical team, rather than managed independently by the patient based on subjective intoxication.

16. Table: how fast tolerance builds by effect ๐Ÿ“Š

Effect Tolerance speed Note
Euphoria / subjective "high" Fast One of the effects that most clearly blunts with repeated use.
Heart rate / acute tachycardia Fast Regular users usually stop noticing the characteristic pulse spike from the onset.
Anxiety reduction Moderate Blunts, but less markedly than euphoria.
Appetite stimulation Moderate Persists longer than the general psychoactive effect for many users.
Pain relief (medical context) Moderate-slow Relevant for patients: the therapeutic benefit may outlast the loss of the high.
Working memory impairment Slow / persistent Doesn't follow the same pattern as euphoria; can persist despite subjective tolerance.
๐Ÿ“‰

Downregulation

Net reduction in the number of available CB1 receptors after sustained daily use, measurable by PET from ~2 weeks.

๐Ÿ“ˆ

Recovery

Begins at 48h, improves substantially around 2 weeks, approaches baseline around 4 weeks of abstinence.

17. Myths vs. reality โœ…โŒ

Myth Reality
"Real tolerance takes months to develop" โœ— PET studies detect measurable CB1 downregulation after just two weeks of daily use.
"If it doesn't get me as high anymore, cannabis has stopped affecting me cognitively" โœ— Working memory impairment doesn't follow the same tolerance pattern as subjective euphoria.
"Tolerance is permanent brain damage" โœ— Neuroimaging studies show measurable recovery of CB1 availability after weeks of abstinence.
"Everyone develops tolerance at the same rate with the same use" โœ— Genetic variants in FAAH and in the CB1 receptor gene itself (CNR1) produce documented individual differences.
"CBD eliminates THC tolerance" โžœ Partially unfounded: CBD can modulate the subjective experience, but there's no solid evidence it reverses CB1 downregulation.
"My THC tolerance protects me if I try synthetic cannabinoids" โœ— Synthetic cannabinoids are usually higher-affinity full agonists at CB1; THC tolerance doesn't equal protection against them.
"Using edibles builds the same tolerance as smoking" โžœ The underlying mechanism (repeated CB1 activation) is the same, but absorption variability in edibles affects how that tolerance is perceived.

18. Frequently asked questions โ“

What exactly is a CB1 receptor?
It's a G protein-coupled receptor, widely distributed across the human brain, that serves as the main binding site for THC and the body's natural endocannabinoids (anandamide and 2-AG), mediating most of cannabis's psychoactive effects on the central nervous system.
How long does it take to develop cannabis tolerance?
Neuroimaging studies show measurable CB1 receptor downregulation after roughly two weeks of daily use, although the subjective magnitude perceived by the user tends to keep increasing with continued use over time.
Is cannabis tolerance permanent?
Not according to the available evidence. PET studies show measurable recovery of CB1 receptor availability after several weeks of abstinence, indicating the process is largely reversible.
Why don't I feel the "high" anymore but I still notice it affecting my memory?
Because different effects of cannabis tolerate at different rates. Subjective euphoria tends to blunt relatively quickly, while working memory impairment doesn't appear to follow that same accelerated tolerance pattern.
Do we all develop the same tolerance with the same use?
No. There are known genetic variants, both in the FAAH enzyme and in the CB1 receptor gene itself (CNR1), that influence how each person processes repeated THC exposure, producing documented individual differences.
Is cannabis more dangerous for teenagers because of this mechanism?
The evidence suggests there is indeed a differential vulnerability, since the endocannabinoid system and reward circuits are still actively developing during adolescence, which could make them more sensitive to lasting remodeling from repeated THC exposure.
Does CBD reduce THC tolerance?
There's no solid clinical evidence conclusively supporting that claim. CBD can modulate the subjective THC experience through indirect mechanisms, but that's different from reversing CB1 receptor downregulation.
Does my tolerance to natural cannabis protect me against Spice or K2?
Not reliably. Many synthetic cannabinoids act as high-affinity full agonists at the CB1 receptor, a different and more intense activation mechanism than THC's, so tolerance built up against cannabis doesn't equal protection against them.
Why do edibles sometimes affect me much more than expected even though I have tolerance?
Because oral THC absorption is more variable and unpredictable than smoking, and in users not accustomed to that route, an initial sensitization effect can occur instead of the expected tolerance pattern.
How much abstinence time is needed to "reset" tolerance?
According to neuroimaging studies, recovery starts to register from 48 hours, improves substantially around two weeks, and approaches baseline levels around four weeks of abstinence in daily users, although the exact pace varies by brain region and individual use history.
Do all brain regions recover CB1 receptors at the same rate?
No. The hippocampus and striatum show relatively faster recovery patterns in some studies, while certain cortical regions may take longer to fully normalize.
Does pain relief from medical cannabis also develop tolerance?
Yes, but evidence suggests the analgesic effect may tolerate at a slower rate than the subjective psychoactive effect, which is relevant for patients assessing whether their treatment is still effective even though they no longer feel the same "high."
What's the difference between desensitization, internalization, and downregulation?
They're three progressive phases of the same adaptive process: desensitization reduces the receptor's signaling efficiency without moving it; internalization pulls receptors from the cell surface inward in a partially reversible way; downregulation involves a net, more lasting reduction in the total number of available receptors.
Is there a test to measure my own tolerance at the receptor level?
Not in any accessible way outside a research setting. The techniques that have allowed researchers to observe CB1 downregulation, such as positron emission tomography (PET) with specific tracers, are clinical research procedures, not tools available for personal self-assessment.
Where can I find a practical guide to doing a tolerance break?
Beetle Print has a dedicated article in this same educational series covering tolerance breaks (t-breaks) specifically, with practical duration recommendations based on your usage pattern and what to expect at each stage.
Does smoking more "trick" tolerance and restore the original effect?
Not sustainably. Increasing the dose can partially compensate for downregulation in the short term, but it keeps the CB1 receptor system under the same sustained exposure that caused the tolerance in the first place, so it tends to perpetuate or even accelerate the same adaptive process rather than reverse it.
Does tolerance to edibles behave the same as tolerance from smoking?
The underlying mechanism at the CB1 receptor is the same, but the exposure kinetics are different: edibles create a slower-onset but more prolonged activation, partly due to the 11-hydroxy-THC metabolite, which can make perceived tolerance between the two routes not directly comparable.
Important notice

This article is for informational and educational purposes only and summarizes published scientific research findings. It does not constitute medical advice. The neuroimaging studies cited are based on specific samples and protocols; individual response to tolerance and abstinence may vary. If you have questions related to cannabis use and personal health, consult a medical professional.

Understand your consumption through science, not myth

At Beetle Print, we believe the best harm reduction starts with understanding what's really happening in your body โ€” without exaggerating the risk or downplaying it.

View the Beetle Print catalog

Sources consulted

  • Hirvonen, J. et al. โ€” "Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers", Molecular Psychiatry, 17, 642โ€“649 (2012).
  • Ceccarini, J. et al. โ€” "[18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users", Addiction Biology (2015).
  • PMC โ€” "Why do cannabinoid receptors have more than one endogenous ligand?" โ€” on anandamide and 2-AG.
  • MDPI โ€” "The Endocannabinoid System in Human Disease: Molecular Signaling, Receptor Pharmacology, and Therapeutic Innovation" (2025).
  • Springer, Neurotherapeutics โ€” "The Endocannabinoid System and its Modulation by Phytocannabinoids".
  • ScienceDirect โ€” "Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance".
  • PMC โ€” "Tolerance to Effects of High-Dose Oral ฮ”9-Tetrahydrocannabinol and Plasma Cannabinoid Concentrations in Male Daily Cannabis Smokers".
  • Science Advances โ€” "Endocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice" (2020).
  • Weill Cornell Medicine / ScienceDaily โ€” coverage of the study on the FAAH genetic variant and THC reward in adolescents.
  • ScienceDirect โ€” "Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits".
  • Weedmaps โ€” "Marijuana Tolerance: How Your Genes Influence Your Interaction With Cannabis".
  • General documentation on cross-tolerance of synthetic cannabinoids as high-affinity full agonists at CB1 โ€” see also this series' article on Spice/K2.

This article is informational and educational in nature and synthesizes findings from peer-reviewed scientific research. It does not replace the advice of a medical professional. The percentages and timeframes cited come from studies with specific samples and protocols, and individual response may vary based on genetic factors, consumption pattern, and general health status.

Retour au blog